Literature DB >> 20862240

'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting.

W Dewilde1, F W A Verheugt, N Breet, J J Koolen, J M Ten Berg.   

Abstract

Chronic oral anticoagulant treatment is obligatory in patients (class I) with mechanical heart valves and in patients with atrial fibrillation with CHADS2 score >1. When these patients undergo percutaneous coronary intervention with placement of a stent, there is also an indication for treatment with aspirin and clopidogrel. Unfortunately, triple therapy is known to increase the bleeding risk. For this group of patients, the bottom line is to find the ideal therapy in patients with indications for both chronic anticoagulation therapy and percutaneous intervention to prevent thromboembolic complications such as stent thrombosis without increasing the risk of bleeding. (Neth Heart J 2010;18:444-50.).

Entities:  

Keywords:  Atrial Fibrillation; Dual Antiplatelet Therapy; Mechanical Valves; Oral Anticoagulation; Percutaneous Coronary Intervention; Triple Therapy

Year:  2010        PMID: 20862240      PMCID: PMC2941131          DOI: 10.1007/BF03091812

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  49 in total

1.  ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention).

Authors:  Sidney C Smith; Ted E Feldman; John W Hirshfeld; Alice K Jacobs; Morton J Kern; Spencer B King; Douglass A Morrison; William W O'Neill; Hartzell V Schaff; Patrick L Whitlow; David O Williams; Elliott M Antman; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-01-03       Impact factor: 29.690

2.  Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction.

Authors:  Stephen J Mattichak; Pamela S Reed; Michael J Gallagher; Judith A Boura; William W O'Neill; Joel K Kahn
Journal:  J Interv Cardiol       Date:  2005-06       Impact factor: 2.279

3.  Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.

Authors:  Zakaria Khurram; Eric Chou; Robert Minutello; Geoffrey Bergman; Manish Parikh; Srihari Naidu; S Chiu Wong; Mun K Hong
Journal:  J Invasive Cardiol       Date:  2006-04       Impact factor: 2.022

Review 4.  Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

Authors:  Michelle L O'Donoghue; Eugene Braunwald; Elliott M Antman; Sabina A Murphy; Eric R Bates; Yoseph Rozenman; Alan D Michelson; Raymond W Hautvast; Peter N Ver Lee; Sandra L Close; Lei Shen; Jessica L Mega; Marc S Sabatine; Stephen D Wiviott
Journal:  Lancet       Date:  2009-08-31       Impact factor: 79.321

5.  Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.

Authors:  Andrea Rubboli; Milena Milandri; Cristina Castelvetri; Benilde Cosmi
Journal:  Cardiology       Date:  2005-07-12       Impact factor: 1.869

6.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

7.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Genetic determinants of response to clopidogrel and cardiovascular events.

Authors:  Tabassome Simon; Céline Verstuyft; Murielle Mary-Krause; Lina Quteineh; Elodie Drouet; Nicolas Méneveau; P Gabriel Steg; Jean Ferrières; Nicolas Danchin; Laurent Becquemont
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

10.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

Authors:  Gilles Montalescot; Stephen D Wiviott; Eugene Braunwald; Sabina A Murphy; C Michael Gibson; Carolyn H McCabe; Elliott M Antman
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

View more
  2 in total

1.  'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting.

Authors:  W Dewilde; F W A Verheugt; N Breet; J J Koolen; J M Ten Berg
Journal:  Neth Heart J       Date:  2010-09       Impact factor: 2.380

2.  Managing the Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients on Oral Anticoagulation.

Authors:  Darshni Arishta Jhagroe; Jurriën Maria Ten Berg
Journal:  Interv Cardiol       Date:  2015-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.